**Table 1. Study populations included in the analysis after quality control and exclusion of biallelic pathogenic/likely pathogenic *PRKN* SNV and CNV carriers.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | McGill University | Columbia University | Sheba Medical Center |
| Variable | Patients (n=1,034) | Controls (n=2,451) | Patients (n=939) | Controls (n=491) | Patients (n=654) | Controls (n=521) |
| Age, ya,b (SD) | 59.09 (10.58) | 53.35 (14.17) | 59.34 (11.56) | 64.56 (9.87) | 60.50 (11.82) | 39.24 (14.38) |
| Early onset patientsc/total with available AAO data, No. (%) | 164/747 (22%) | NA | 212/929 (23%) | NA | 122/632 (19%) | NA |
| Male, No. (%) | 654 (64%) | 1,160 (47%) | 611 (65%) | 177 (36%) | 408 (63%) | 306 (59%) |
| Ashkenazi Jewish ancestry, No. (%) | 0 (-) | 0 (-) | 210 (22%) | 91 (19%) | 654 (100%) | 521 (100%) |

a Data are presented as mean (SD).

b Data for age and sex are missing for 321 (12%) patients and 246 (7%)

c Early onset is defined as AAO < 50 years

 controls. Difference of age and sex between patients and controls were adjusted in our analysis.

Abbreviations: y, years; SD, standard error; AAO, age at onset; No, number; NA, not applicable;